Screener
CytomX Therapeutics CTMX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued liabilities | 12,353 | 14,197 |
| Operating lease liabilities - short-term | 1,496 | 4,240 |
| Deferred revenue, current portion | 24,073 | 26,877 |
| Total current liabilities | 39,861 | 46,615 |
| Deferred revenue, net of current portion | 30,617 | 1,590 |
| Operating lease liabilities - long term | 4,208 | — |
| Other long-term liabilities | 4,472 | 4,353 |
| Total liabilities | 79,158 | 52,558 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's total current liabilities?
- CytomX Therapeutics (CTMX) reported total current liabilities of $39.86M in Q2 2026.
- How has CytomX Therapeutics's total current liabilities changed year-over-year?
- CytomX Therapeutics's total current liabilities increased by 1.6% year-over-year, from $39.22M to $39.86M.
- What is the long-term trend for CytomX Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), CytomX Therapeutics's total current liabilities has grown at a -7.3% compound annual growth rate (CAGR), from $68.11M to $46.62M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about CytomX Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude